It is our mission to secure Indiana’s position as a global leader in life sciences by advocating, connecting, promoting, and delivering tangible benefits on behalf of our diverse corporate members. | |
News From Around the Industry | |
|
Technical and Business Assistance (TABA) for NIH SBIR/STTR-Funded Projects
TABA is an excellent resource for funding activities that are not normally allowed with federal funding. Examples of technical assistance that can be supported are intellectual property protections; market research and/or validation; development of regulatory plans; or development of manufacturing plans.
Companies may request up to $6,500 per year for a Phase I project and up to $50,000 per Phase II (across all years) for assistance.
Read on
Source: BBCetc
| |
FDA Provides Clarity on Premarket Submissions for Medical Device Software
by Dan Goldstein
Software systems have become key elements in the design and function of medical devices as orthopedic companies fill product portfolios with high-tech solutions. FDA is keeping pace with this evolving landscape with guidance documents that outline what the agency considers when reviewing premarket submissions of software-enabled devices.
Read More
Source: BONEZONE
| |
16 Tech plans two more buildings after early leasing success
By Mickey Shuey, Indianapolis Business Journal
With most of its existing office space already leased and more than 280 apartments now under construction, 16 Tech Community Corp. is embarking on plans for the next phase of development at its eponymous 50-acre campus on the northwestern edge of downtown Indianapolis.
The master developer has begun pre-leasing two new buildings planned for the entrepreneurism-innovation district south of the intersection of West 16th Street and Indiana Avenue: a 100,000-square-foot laboratory building and a 40,000-square-foot office structure that would be dedicated to sports- and health-focused tenants.
| |
|
ARPA-H launching antimicrobials research project
The Advanced Research Projects Agency for Health is launching a $100 million effort to discover new antimicrobials that are effective against drug-resistant bacterial infections, which kill an estimated 1 million people worldwide each year. More than 35,000 people in the US die of drug-resistant bacterial infections annually, according to the CDC, and health experts believe the problem is worsening.
Full Story: Reuters (9/27)
| |
With BIO Business Solutions (BBS), IHIF members are eligible for discounts and savings on a wide variety of products and services geared towards life sciences companies and general business needs. From lab supplies, waste removal and insurance, to office supplies and credit cards, there is something here for every company. Explore your options and enjoy the benefits of being an IHIF member! | |
BIO Business Solutions - Special Discounts for IHIF Members | |
|
Featured Program
Please share with someone in your company who would find this helpful
| BIO Business Solutions provides cost-savings offers to eligible IHIF Members. To learn more about the programs and services available, please click here. Not an IHIF member? Join today! | |
UniFirst, a leading supplier of workwear programs for businesses big and small since 1936, provides a range of apparel from traditional uniforms and industrial wear to protective clothing and “corporate casual” attire. Serving over 275,000 customers throughout the United States and Canada, UniFirst outfits more than 1.5 million people in their work clothes each business day and offers customers rental, lease, and purchase programs to enhance their business image at the very best value. | |
|
IHIF Member Benefits
- Uniform and facility service savings of 30-50%
- Hygienically clean garments & UHF Chip technology
- Dedicated customer service team
- Customer favorable terms and conditions
- No price increases for 3 years
- Free lab coat pressing included with rental program
- Free company and name emblems on initial installation
- No upfront program investment
- 1-week complimentary service upon new agreement execution
| |
Be sure to check out the new IHIF Member Directory featuring company descriptions and an alphabetical listing. | |
Welcome New IHIF Members! | |
|
Kovina Therapeutics is a preclinical drug discovery company focused on stopping human papillomavirus (HPV) premalignant infections before cancer develops and treating HPV cancers after detection. Kovina's novel small molecule antiviral compounds bind to and inactivate a key HPV protein always expressed in early, premalignant, and cancerous pathologies. Directory Link
| |
|
Family owned and operated, Biodyne USA is an environmental biotechnology company focused on harnessing the power of naturally occurring, beneficial microorganisms and other sustainable technologies for use in a variety of agricultural and environmental applications.
At Biodyne USA, we leverage close to 30 years of R&D to deliver innovative biological products. Our core products are made in the USA and consist of 100% natural, highly diverse, proprietary microbial teams with proven beneficial capabilities providing economical solutions to a variety of Environmental applications and Agricultural production systems and are used on millions of acres every year! Directory Link
| |
|
Product Realization for Pre- and Post-Market Medical Devices in the US and EU
As a full-service provider, Kapstone Medical is more than just an engineering firm or regulatory consultancy. Our mission is to inspire, equip, and guide medical device companies to market, providing a single-source solution to all the challenges along the way. While we’re experts in development, manufacturing, regulatory affairs, quality system implementation and more, we’ll adapt our model to your unique needs and onboard whenever you’re ready for us. We’re flexible in our process so that you don’t have to be. Directory Link
| |
|
At Aurorium, we believe in the power of possibility; through specialty ingredients and performance-enhancing materials, Aurorium makes it possible for companies around the world to create life-improving products that make the world a better place. In healthcare, we are focused on providing solutions that enhance drug delivery, feature biocompatibility for optimized performance, and support human health. Directory Link
| |
|
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing and packaging of complex oral solid dose, liquid, and semi-solid pharmaceutical Rx and OTC products for clinical and commercial uses. Directory Link
| BVS Sight Inc. was established in late 2022 to develop, produce and market a Smart Soft Contact Lens System continuously to monitor IOP and manage glaucoma. BVS Sight is a Boomerang Studio company and is working with Purdue University Weldon School of Biomedical Engineering and the Indiana University School of Optometry to bring this product to market and solve an unmet need in vision care. Directory Link | |
|
GeniPhys is developing and commercializing its patented Collymer™ technology -a first-of-a-kind polymerizable (scaffold-forming) collagen that supports custom design and fabrication of collagen materials for accelerated and improved tissue restoration and regeneration. Directory Link
| |
|
Levisonics is re-imagining the blood coagulation testing with its safer, convenient and more comprehensive coagulation analyzer using a novel non-contact drop-of-blood platform technology. Directory Link
| |
|
Biotechnology Venture Creation – Mental Health & Neuroscience Drug Discovery & Development Focus Directory Link
| |
|
Founded by serial entrepreneur Dr. Don Brown in 2016, LifeOmic works with health care providers, researchers, and health-focused enterprises in their pursuit of precision health care to improve patient outcomes. We believe in the promise of precision health but see a large gap in the current healthcare IT landscape and its ability to fulfill this promise.
Healthcare today suffers from huge amounts of scattered, disconnected data at a time when we need harmonization and consolidation of the numerous sources of key information to make precision health a reality. Leaning on our cloud and mobile software expertise, we set out to fill this crucial gap.
Directory Link
| |
|
Quantigen specializes in sample-to-answer method development and validation across a broad array of applications. For more than a decade, we have leveraged our expertise in molecular biology, biotechnology, and regulatory oversight to design customized, cost-effective workflows for our clients in three core areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.
Directory Link
| |
|
Reveal Risk (RR) delivers outstanding cybersecurity and data protection outcomes for clients by using a business-risk-driven approach that focuses cybersecurity programs on the most impactful activities, aligned with the client’s most important assets and information. This tailored approach (based on decades of corporate experience) helps company leaders to reduce risk most effectively and efficiently.
At its core, RR is driven to help cyber and business leaders focus their efforts, unlock the potential of their technology, and build effective cyber programs that empower the businesses they protect. To deliver differentiated engagements and tangible results for clients, RR focuses first on people, building a world-class team of cybersecurity experts. They maintain a high-growth culture where employees learn, develop, and thrive. By following this simple formula, RR has produced fantastic results nationally as a testament to what is possible in Indiana with Hoosier entrepreneurial spirit. Directory Link
| | |
|  |
Follow IHIF on Twitter to keep up with all of the latest news, events, and exclusive member benefits!
| | |
As a member benefit, IHIF is pleased to share and highlight member company news! Please send press releases to info@ihif.org. | |
Need help telling your story?
IHIF is able to provide access to contract/custom press release and writing services. (Fee for service). Inquiries welcome - click here
| |
|
Notre Dame tops $200 million in annual research funding for third straight year
During fiscal year 2023, the University of Notre Dame received nearly $216 million in new research award funding, topping $200 million for the third year in a row. This total includes 824 separate awards, the largest number the University has ever received.
Read More
| |
New bio-based glues from Purdue form adhesive bonds that grow stronger in water
Patent-pending formulations could be used to restore coral reefs and have applications in construction, biomedical, dental, food, cosmetics and other fields
Read More
| |
Setting the Tone: IU Health Taps Local Firms to Construct First Major Building on Expanded Downtown Campus
By: Jack Quigley, Building Excellence Magazine
Indiana University Health is constructing a medical office building (MOB) and parking garage in downtown Indianapolis at the intersection of 16th Street and Capitol Avenue called Capitol View. Together with the new downtown hospital (being built across Capitol Avenue to the west and connected via glass pedestrian bridge), Capitol View will set the tone for IU Health’s multi-billion-dollar new downtown hospital and form a gateway into the IU Health medical campus.
Read More
| |
|
What We're Following at Home and on the Hill
| |
BIO's Statement on the ORPHAN Cures Act a "welcome and bipartisan fix" to the IRA's negative impact on drug development
Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks:
"This legislation is a welcome and bipartisan fix to the Inflation Reduction Act’s (IRA) negative impact on the development of drugs to treat rare diseases.
"Encouraging R&D for drugs to treat rare diseases is difficult as is. By definition, orphan drugs benefit small patient populations, making investment in this space incredibly risky. But there is tremendous need for these treatments. Fewer than 5 percent of rare diseases have an FDA approved treatment. We have repeatedly warned that the IRA -- by subjecting drugs that can treat more than one rare disease to government price controls -- creates even more barriers to investment into follow-on research and development for orphan drugs".
Read Full Statement
| |
|
House Budget Committee Seeks Input on Healthcare Spending
IHIF Submitting Comments
On August 22, 2023, the House Budget Committee established the Health Care Task Force to examine key drivers of our nation’s health care spending and solutions to improve health outcomes while bending down the debt curve.
The Task Force is soliciting feedback from stakeholders and experts on solutions to improve outcomes, reduce federal health care spending in the budget, as well as opportunities to build upon CBO’s ability to project the impact of health care policies.
IHIF will be submitting comments in response to this request and would like to hear from stakeholders in Indiana. Please contact us, with your comments, at info@ihif.org before Wednesday, October 11, 2023.
If you wish to respond directly, please send comments to hbcr.health@mail.house.gov no later than October 15, 2023.
Read Full RFI
| |
Op-Ed: How early detection can help bridge cancer gap in Indiana
Senior citizens are at the greatest risk of developing cancer and highly effective multi-cancer early detection (#MCED) tests can have a transformative impact on their health outcomes. Ensuring that the Medicare program, which is how most seniors receive their health insurance, can cover these tests must be a priority for federal lawmakers.
Read more
| |
|
New study IDs 3 ways pharma R&D will be hurt by IRA price negotiations
Findings from a new University of Chicago study partly backed by Gilead Sciences identified three ways the Inflation Reduction Act will affect research and development of pharmaceutical companies, resulting in 79 fewer new small-molecule drugs reaching the market and their intended patients in the next 20 years. The research showed the IRA 's financial impact could have been underestimated because the law would cause up to an 8% drop in overall industry revenue, a 12.3% cutback in R&D, and the reduced investment in R&D in effect would convert to "79 fewer small molecule drugs or 188 indications, and 116.0 million life years lost over the next 20 years," the study authors wrote.
Full Story: Fierce Biotech (9/6)
| |
The Indiana Health Industry Forum provides guidance and leadership on public policy issues that contribute to innovation in the health science sector, deliver therapies to patients in need, and further the development and growth of our member companies. IHIF works at the federal and state level and partners with several other organizations and groups to support specific initiatives and legislation.
| |
|
The 2024 Call for Sessions is open!
Share your knowledge as part of the BIO International Convention 2024 program content.
Our Call for Sessions platform is now open, so this is the perfect time to start thinking about your areas of expertise and how to share your unique insights at our industry's largest event. Learn more.
Our Key Focus Areas for 2024 are:
| |
|
· Biomanufacturing
· Brain Health
· Business Development & Finance
· Cell & Gene Therapy and Genome Editing
· Clinical Trials Innovations
· Diagnostics & Personalized Medicine
· Digital Health
· Diversity, Equity, and Inclusion in Biotech
· Emerging Opportunities in Global Markets
| | |
|
· Infectious Disease & Vaccines
· Intellectual Property
· Next Generation Biotherapeutics
· Oncology
· Orphan & Rare Disease
· Patient Advocacy
· Regulatory Innovation
· Translational Research
· Value, Patient Access & Reimbursement
| |
|
Download our 2024 Submission Guide to see tips for success
and important details.
DOWNLOAD GUIDE
| |
|
New England Venture Summit
IHIF Members Save $450 Using Promo Code IHIFVIP
Get Connected. Get Funded. Grow Faster.
Register now to join leading VCs, corporate VCs, angel investors, investment bankers, and CEOs of venture-backed, emerging, and early-stage companies at The New England Venture Summit being held on December 12-13, 2023.
Presented by youngStartup Ventures, The 2023 New England Venture Summit provides an unparalleled opportunity for startups to meet, network, and showcase their innovative investment opportunities to a leading group of investors.
A select group of more than 100 Top Innovators from the tech, medtech, cleantech, life sciences/healthcare, and fintech sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers and Strategic Partners.
| |
|
AdvaMed - The MedTech Conference
Anaheim, CA
October 9-11, 2023
IHIF Member Discount - Save 10% with promo code SPO23
The MedTech Conference in Anaheim, California, October 9-11, 2023, will help you look ahead and create new possibilities. Featuring world-class speakers, a cross-cutting educational program, invaluable networking and next-level technology, this forum for transformational ideas is a can’t-miss event for the industry’s prominent and most promising companies. Visit themedtechconference.com to register today!
| |
|
Indiana Life Sciences Summit 2023
Thursday, November 9, 2023 9:30 AM
Mavris Arts & Event Center
Indiana's Role in the Alzheimer's Battle: Meaningful Research, Clinical Interventions, and Public Health
Nearly 7 million Americans aged 65 and older have Alzheimer’s dementia according to the Alzheimer’s Association. With about 10,000 Baby Boomers turning 65 each day, the number of people affected will continue to jump. In fact, from 2020 to 2025, the number of Hoosiers with Alzheimer’s will jump 18 percent.
Fortunately for people everywhere, Indiana’s life sciences community is focused on conquering this vexing, devastating disease. Join us November 9 for our annual Indiana Life Sciences Summit and learn how major research universities, pharmaceutical and diagnostic companies, biotech startups, and leading advocacy groups in Indiana are disrupting the landscape and affecting how treatment could change for patients. Check out the registration page for our early-bird ticket price now through September 18. Our event will include light breakfast, lunch, and networking opportunities at the end of the day -- allowing you to distill what you've heard and continue this important conversation.
Register Now
| |
Save the Date - FEBRUARY 27-29, 2024
THE LODGE AT TORREY PINES
SAN DIEGO, CALIFORNIA
This conference is an exclusive global partnering forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Join us next February 2024, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers from around the globe.
The partnering conference and the relationships you build promise to be fruitful for your business ventures this year and for many years to come. We are excited by the prospect of continuing an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world.
Learn More
| |
|
2023 - 2024
Indiana Life Sciences
Collaboration Conference Series
Since 2006, the Center for the Business of Life Sciences (CBLS) has provided a forum for various players in healthcare and life sciences to consider, discuss, and debate key business strategy issues. In presenting the Indiana Life Sciences Collaboration Conference Series, CBLS brings together key players from industry, academia, government, and economic development communities to share ideas and expertise.
Upcoming Topics
Nov. 10, 2023 - Closing the Gap of Health Inequalities
Feb 16, 2024 - Industry Impact of the Inflation Reduction Act
Apr 19. 2024 - Tech: Don't be Afraid of Healthcare!
CLICK FOR MORE INFO & REGISTER NOW
| |
Join IHIF - Become a Member Today! | |
About IHIF Membership
Now is a great time to become a member of the Indiana Health Industry Forum! Join your voice to over 150 current member companies to impact the strategic direction of Indiana's health science sector.
Membership in IHIF offers a number of solutions:
- Promote your business, locally, nationally, and globally.
- Support the industry in the state and contribute directly to its growth and direction.
- Find others who share your interests and build your business network.
- Lend your voice to public policies that support innovation.
- Directly impact your bottom line with significant savings and discount programs exclusively for IHIF members.
To complete a membership application, click here.
| | | | |
